Prospective European Multicenter Study on Aortic Valve Replacement: (E-AVR Registry)

Traditional and transcatheter surgical treatments of severe aortic valve stenosis (SAVS) are increasing in parallel with the improved life-expectancy. Recent randomized trials (RCTs) reported comparable or non-inferior mortality with transcatheter treatments compared to traditional surgery. However, RCTs have the limitation of being a mirror of the predefined inclusion/exclusion criteria, without reflecting the "real clinical world". Technological improvements have recently allowed the development of minimally invasive surgical accesses and the use of sutureless valves, but their impact on the clinical scenario is difficult to assess because of the monocentric design of published studies and limited sample-size. A prospective multicentre registry including all patients referred for a surgical treatment of SAVS (traditional, through full-sternotomy; minimally-invasive; or transcatheter; with both "sutured" and "sutureless" valves) will provide a "real-world" picture of available results of current surgical options, and will help to clarify the "grey zones" of current guidelines. E-AVR is a prospective observational open registry designed to collect all data from patients admitted for SAVS, with or without coronary artery disease, in 16 cardiac surgery Centres located in six countries (France, Germany, Italy, Spain, Switzerland, and United Kingdom). Patients will be enrolled over a 2-year period and followed-up for a minimum of 5 years to a maximum of 10 years after enrolment. Outcome definitions are concordant with VARC-2 criteria and established guidelines. Primary outcome is 5-year all-cause mortality. Secondary outcomes aim at establishing "early" 30-day all-cause and cardiovascular mortality, as well as major morbidity, and "late" cardio-vascular mortality, major morbidity, structural and non-structural valve complications, quality of life and echocardiographic results. The study protocol is approved by Local Ethics Committees. Any formal presentation or publication of data will be considered as a joint publication by the participating physician(s) and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE) for authorship.

NCT Number	NCT03143361
Lead Sponsor	University of Parma Collaborators: University of Genova, University Hospitals, Leicester, University of Hamburg-Eppendorf, San Camillo Hospital, Rome, University of Turin, Italy, Centre Hospitalier Universitaire de Besancon, University Hospital, Udine, Italy, Hospital Clinic of Barcelona, University of Lausanne Hospitals, Hopital Universitaire Robert-Debre, Paracelsus Medical University, University of Campania Luigi Vanvitelli, University of Texas, Southwestern Medical Center at Dallas, Clinique Pasteur, Cardiocentro Ticino, Universita di Verona
Conditions	Aortic Valve Stenosis, Valve Heart Stenosis
Enrollment	8,000 participants
Start Date	2017-11-01
Primary Completion	2019-11-30 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2020-04-03